Advantages of α-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients

被引:114
作者
Johnston, PS
Lebovitz, HE
Coniff, RF
Simonson, DC
Raskin, P
Munera, CL
机构
[1] Bayer Pharmaceut, West Haven, CT 06516 USA
[2] SUNY Hlth Sci Ctr, Brooklyn, NY 11203 USA
[3] Brigham & Womens Hosp, Boston, MA 02115 USA
[4] Univ Texas, SW Med Ctr, Dallas, TX 75235 USA
关键词
D O I
10.1210/jc.83.5.1515
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The objective of this study was to determine the safety, efficacy, and tolerability of the alpha-glucosidase inhibitor miglitol vs. the sulfonylurea glyburide in the treatment of elderly patients with type 2 diabetes mellitus, inadequately controlled by diet alone. This was a double-blind, randomized, placebo-controlled, 1-yr trial of miglitol 25 mg TID and 50 mg TID compared with placebo and a titrated dose of glyburide in a parallel group comparison study conducted in 30 out-patient sites across the United States. Four hundred eleven (411) diet-treated patients age 60 yr or greater were randomized to receive either placebo TID (n = 101), miglitol 25 mg TID (n = 104), miglitol 50 mg TID (n = 102), or a once-daily dose of glyburide titrated based on fasting plasma glucose (FPG) (n = 104), for a period of 56 weeks. Efficacy was assessed by glycated hemoglobin (HbA1c), fasting and post-meal glucose, insulin, and lipid levels, and by 24-h urinary excretion of glucose and albumin. Safety and tolerability were assessed by tabulation of adverse events, periodic laboratory determinations, and home blood glucose monitoring. HbA(1)c treatment effects (placebo-subtracted change in HbA(1)c from baseline) at the 1-yr endpoint were -0.49%, -0.40%, and -0.92% in the miglitol 25 mg TID, miglitol 50 mg TID, and glyburide groups, respectively (P < 0.05 - 0.01 vs, placebo). Postprandial insulin levels were significantly greater than placebo and miglitol in the glyburide group (P < 0.01). Hypoglycemia, weight gain, and both routine and serious cardiovascular events were more frequent in the glyburide group (P < 0.05 - 0.01 vs. placebo or miglitol groups). Diarrhea (or soft stools) and flatulence were more common in both miglitol groups than in the other two groups in a dose-dependent manner, but resulted in relatively few study dropouts. Treatment with miglitol offers the elderly type 2 diabetic patient significant reductions in daylong glycemia as measured by HbA(1)c. The greater HbA(1)c reductions seen with once-a-day glyburide occurred at a cost of significant increases in weight, insulin levels, and the incidences of clinical and subclinical hypoglycemia, which did not occur in the miglitol groups, alpha-glucosidase inhibitors are a useful and relatively safe therapeutic option in the elderly patient with type 2 diabetes.
引用
收藏
页码:1515 / 1522
页数:8
相关论文
共 19 条
[1]  
[Anonymous], 1970, Diabetes, V19, P747
[2]  
[Anonymous], 1996, Diabetes Rev
[3]   THE INFLUENCE OF AGING ON HEMOGLOBIN A1C (HBA1C) [J].
ARNETZ, BB ;
KALLNER, A ;
THEORELL, T .
JOURNALS OF GERONTOLOGY, 1982, 37 (06) :648-650
[4]  
ASPLUND K, 1983, DIABETOLOGIA, V24, P412
[5]   BENEFITS AND RISKS WITH GLYBURIDE AND GLIPIZIDE IN ELDERLY NIDDM PATIENTS [J].
BRODOWS, RG .
DIABETES CARE, 1992, 15 (01) :75-80
[6]  
CONIFF RF, 1996, DIABETES S2, V45, pA221
[7]  
DAVIDSON JA, 1997, DIABETES S1, V46, pA156
[8]  
DAVIDSON MB, 1991, DIABETES MELLITUS DI, P566
[9]   HYPERINSULINEMIA AS A PREDICTOR OF CORONARY HEART-DISEASE MORTALITY IN A HEALTHY POPULATION - THE PARIS PROSPECTIVE-STUDY, 15-YEAR FOLLOW-UP [J].
FONTBONNE, A ;
CHARLES, MA ;
THIBULT, N ;
RICHARD, JL ;
CLAUDE, JR ;
WARNET, JM ;
ROSSELIN, GE ;
ESCHWEGE, E .
DIABETOLOGIA, 1991, 34 (05) :356-361
[10]   THE IMPACT OF AGING ON ADRENERGIC-RECEPTOR FUNCTION - CLINICAL AND BIOCHEMICAL ASPECTS [J].
HEINSIMER, JA ;
LEFKOWITZ, RJ .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1985, 33 (03) :184-188